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Abstract
The lack of new antibiotic classes calls for a cautious use of existing agents. Yet, every 10 min, almost two tons
of antibiotics are used around the world, all too often without any prescription or control. The use, overuse and
misuse of antibiotics select for resistance in numerous species of bacteria which then renders antimicrobial
treatment ineffective. Almost all countries face increased antimicrobial resistance (AMR), not only in humans but
also in livestock and along the food chain. The spread of AMR is fueled by growing human and animal populations,
uncontrolled contamination of fresh water supplies, and increases in international travel, migration and trade. In this
context of global concern, 68 international experts attending the fifth edition of the World HAI Resistance Forum in
June 2015 shared their successes and failures in the global fight against AMR. They underlined the need for a “One
Health” approach requiring research, surveillance, and interventions across human, veterinary, agricultural and
environmental sectors. This strategy involves concerted actions on several fronts. Improved education and increased
public awareness are a well-understood priority. Surveillance systems monitoring infections need to be expanded
to include antimicrobial use, as well as the emergence and spread of AMR within clinical and environmental
samples. Adherence to practices to prevent and control the spread of infections is mandatory to reduce the
requirement of antimicrobials in general care and agriculture. Antibiotics need to be banned as growth promoters
for farm animals in countries where it has not yet been done. Antimicrobial stewardship programmes in animal
husbandry have proved to be efficient for minimising AMR, without compromising productivity. Regarding the use
of antibiotics in humans, new tools to provide highly specific diagnoses of pathogens can decrease diagnostic
uncertainty and improve clinical management. Finally, infection prevention and control measures – some of
them as simple as hand hygiene – are essential and should be extended beyond healthcare settings. Aside from
regulatory actions, all people can assist in AMR reduction by limiting antibiotic use for minor illnesses. Together, we
can all work to reduce the burden of AMR.
Keywords: Antimicrobial resistance, Antimicrobial conservation, Antibiotic stewardship, One health, Infection
control, Hand hygiene, Surveillance networks, Animal health, Global health, World healthcare-associated infections
resistance forum
* Correspondence: didier.pittet@hcuge.ch
1Infection Control Programme and WHO Collaborating Centre on Patient
Safety, Geneva University Hospitals and Faculty of Medicine, Rue
Gabrielle-Perret-Gentil 4, Geneva, Switzerland
Full list of author information is available at the end of the article
© 2015 Harbarth et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Harbarth et al. Antimicrobial Resistance and Infection Control  (2015) 4:49 
DOI 10.1186/s13756-015-0091-2
Background
Few people outside the medical field know that life-
saving interventions such as chemotherapy, organ
transplants, major surgery, and treatment of auto-
immune diseases or infections in newborns rely on ef-
fective antimicrobials [1]. Beyond humans, there are
also billions of pets, livestock and fish that depend on
these agents, whether as therapeutic or prophylactic
agents, or as growth promoters of questionable value.
Nevertheless, every time we use antibiotics, we create
a selective pressure for bacteria to mutate or exchange
pieces of DNA and possibly develop drug resistance.
Worryingly, global consumption of antibiotics
soared by nearly 70 % between 2000 and 2010 [2]. In
developed countries, between 10 and 20 courses of
therapy are prescribed to each individual before the
age of 18 [3]. Every 10 min, almost two tons of anti-
biotics are used around the world, all too often with-
out any prescription or control [4]. Overuse and
misuse of these agents increase AMR; as a result,
every 10 min a patient dies in the USA or Europe
because antibiotics no longer were effective against
the bacteria responsible for the infection [5, 6]. Such
figures are unknown in other jurisdictions, but they
are likely to be substantially higher in African and
Asian countries.
The burden of AMR at the global level is still
poorly quantified. As yet, no national death register
records “deaths caused by antimicrobial-resistant
infection”, with the notable exception of England &
Wales [7]; therefore, officially no one has ever died of
it. AMR places both humans and animals alike at
greater risk for prolonged disease or death from
bacterial infection [8]. Part of this increased mortality
results from the more complex and less effective anti-
microbial treatments needed for multidrug-resistant
infections. Virulence factor genes that ride with AMR
genes on mobile genetic elements might contribute to
the problem [9].
The recent momentum in policy initiatives to fight
antimicrobial resistance
Time is of the essence for tackling AMR: the longer
action is delayed, the harder control is to achieve in
the long run [10]. As early as the 1990s, a small
number of countries deployed national strategies and
action plans to mitigate this threat, and some of these
successfully reduced antibiotic consumption in humans
and animals, as well as local rates of AMR. But most
countries confronted this problem only more recently.
In 2013, the Global Risks Report of the Word Eco-
nomic Forum stated: “one of the most effective and
common means to protect human life – the use of an-
timicrobials – may no longer be readily available in
the near future” [11]. That same year, science minis-
ters attending the G8 Summit identified AMR as the
“major health security challenge of the 21st century”
[12].
In 2014, India banned over-the-counter sales of antibi-
otics in March, and in April, the World Health
Organization (WHO) published its first global report on
AMR [13]; in July, the British Prime Minister David
Cameron commissioned a prominent economist – Jim
O’Neill – to lead a review on the topic [14]. In Septem-
ber 2014, the United States announced a 5 year plan to
combat the problem domestically and internationally;
6 months later, the Obama administration committed a
historic investment to reduce inappropriate antibiotic
use by 50 % in outpatient settings and 20 % in inpatient
settings by 2020, using 2011 as a reference [15]. Further-
more, the USA have established a Presidential Advisory
Council on Combatting Antimicrobial Resistant Bac-
teria, that is charged with monitoring and coordinating
the actions of the various federal agencies engaged in
tackling AMR.
The 2015 G7 summit called again for intensive inter-
national collaboration in this field, endorsing WHO's
global action plan and One Health approach [16]; but it
remains to be seen if and how this call will translate into
financial resources and concrete actions [17]. Finally, in
a situational analysis published in April 2015 [18], WHO
determined the extent to which effective practices and
structures to address AMR have been set up across the
world and where gaps remain. This country survey fo-
cused on the prerequisites to combat AMR and revealed
that the task ahead is daunting. However, the emerging
global trend is encouraging and there are success stories –
and best practices – to be shared.
This momentum brought together 68 world experts at
the fifth biennial World Healthcare-Associated Infections
Forum in Annecy, France, on 14–16 June 2015. Experts
gathered to address AMR control in low, middle, and
high-income countries using a One Health perspective.
This article summarises the contributions presented dur-
ing that Forum following the strategic objectives of
WHO’s Global Action Plan on AMR (Table 1) [19].
Communication, education and training
Evidence for the effectiveness of public campaigns tar-
geting antibiotic use is still weak, as in most cases their
follow-up evaluations have been limited [20]. Although
awareness campaigns do not provide miracle solutions,
some of them have been quite successful.
Following Belgium’s national awareness campaigns, re-
sistance of Streptococcus pneumoniae to penicillin de-
creased from 18 % in 2000 to 7 % in 2009. The total
number of antibiotic packages consumed per 1000 in-
habitants decreased from 3.6 in 1999–2000 to 2.4 in
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2009–2010 (−33 %). Between 2002–03 and 2008–09, so-
cial security expenditures for the reimbursement of these
drugs dropped by EUR 21 million (−16.7 %). As total ex-
penditure for the six national campaigns between 2002
and 2009 amounted to EUR 2.4 million and cumulative
savings through this same period reached EUR 90 mil-
lion, for every euro invested in the campaigns around
EUR 25 were saved [21]. With its new Strategic Plan
2014–2018 aiming at a 5 % annual reduction in anti-
biotic packages consumed, Belgium anticipates potential
cost savings amounting to EUR 35 million by 2020.
France’s national campaign between 2002 and 2007
decreased the total number of antibiotic prescriptions
per 1000 inhabitants by 26.5 %, with the greatest reduc-
tions (−35.8 %) recorded among children aged 6 to
15 years. Measured in Defined Daily Doses (DDD) per
1000 inhabitants, the corresponding drop in outpatient
antibiotic consumption was less significant, from 32 to
28.5 DDD per 1000 inhabitants per year over the period
[22]. The country still registers high consumption rates
relative to its neighbours, and the impact of the 2002–2007
campaign is fading, with consumption picking up again es-
pecially among the elderly [23, 24].
In 2007, the European Union pioneered an annual
“Antibiotic Awareness Week” and “Antibiotic Awareness
Day”, which was accompanied by a similar effort, “Get
Smart Week” in the USA in 2008. Canada also joined in
2010, followed by Australia in 2012 and New Zealand in
2014. Surprisingly, outpatient antibiotic prescriptions in
Europe seem to have peaked in 1997, well before the im-
plementation of national campaigns on the subject.
Nevertheless, public campaigns have had an impact on
the rate of antibiotic-related consultations and prescrip-
tions [24], with an average reduction of consumption of
1.3–5.6 daily doses per 1000 inhabitants [25]. In the fu-
ture, the EU Commission ambitions to target media
campaigns more effectively at those who lack knowledge,
and at prescribers and pharmacists who have a key role
to play in changing views and behaviour [26].
Assessing the effect and determinants of success of
public awareness campaigns
Monitoring the impact of awareness or educational cam-
paigns remains challenging. The choice of indicators to
monitor campaign outcomes is crucial and for some
comparisons the number of antibiotic packages sold is
more appropriate than the commonly used number of
DDD per 1000 inhabitants [27]. Showing potential sav-
ings to decision-makers can be a strong catalyst for deci-
sions and funding, although economic indicators can be
unhelpful because some broad spectrum antibiotics (e.g.
amoxicillin/clavulanic acid) may be cheaper than narrow
spectrum antibiotics (e.g. flucloxacillin), and prices may
be driven up or down by rapidly evolving production
capacities.
Factors leading to successful awareness campaigns in-
clude carefully designed and simple key messages; target-
ing patients, their families and healthcare workers;
engaging physicians early in the campaign and designing
the key messages with them; using mass media and social
media; and continuously repeating key messages [20, 28].
Despite all the efforts being conducted at the scientific
and regulatory levels, one important factor neither given
significant attention nor investment is the human factor.
Behaviour, whether through individualism, disconnect,
or lack of proper education, is a significant obstacle
moving forward. Increased investments are needed to
not only survey the current behavioural landscape, but
also to define strategies to enact effective change.
Antimicrobial resistance and education
Reinforced education of medical students about the con-
servative prescription of antibiotics is crucial [13, 29]. But
beyond undergraduate and graduate medical curriculums,
training of pharmacists, nurses, midwifes and dentists,
and of veterinarians, veterinary nurses and technicians,
also needs to be reinforced. All these groups of profes-
sionals may be in a position to prescribe antibiotics – or
influence prescriptions – in certain situations [25, 30].
The use of contemporary technologies for education
and training proved highly valuable [31]. Massive Open
Online Courses (MOOCs) can reach a wide array of pro-
fessionals across the world, and smart phones provide an
effective platform for antimicrobial stewardship applica-
tions [32, 33]. Instead of creating new programmes from
scratch, existing good quality MOOCs or apps can be
adapted to local needs.
As educational activities are rarely sufficient to change
behaviour, additional cross-disciplinary research involving
psychologists, medical anthropologists, sociologists and
Table 1 Strategic objectives of WHO’s Global Action Plan on Antimicrobial Resistance
Objectives Means
Improve awareness and understanding of AMR Communication, education and training
Strengthen the knowledge and evidence base on AMR Surveillance and research
Reduce the incidence of infections Sanitation, hygiene and infection prevention measures
Limit the emergence and spread of AMR Optimal use of antimicrobial medicines in human and animal health
Develop new tools to fight AMR New medicines, diagnostic tools, vaccines and other interventions.
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ethnographers is needed to find the most efficient means
to modify behaviours and achieve “culture change”. This
type of research needs to be supported at a global level
and fine-tuned at the local level. It also requires leadership
from ministers of health, leaders in healthcare settings,
and professional societies.
Surveillance and research
Global antibiotic use and antimicrobial resistance
The Center for Disease Dynamics, Economics & Policy
(CDDEP) has surveyed human consumption of antibi-
otics, finding a 36 % per capita increase between 2000
and 2010 [2]. Whereas consumption decreased in coun-
tries such as Mexico or Chile, it sharply increased in
many low-income and middle-income countries (LMIC).
Figure 1 summarises the annual growth rate in anti-
microbial use in 69 countries. Globally, colistin and car-
bapenem availability and consumption have increased
massively [2]. At country level, the main drivers of in-
creased antibiotic consumption are rising incomes (as
more people demand antibiotics for minor infections),
insufficient investment in public health capacity, and a
significant background of infectious diseases [34].
Increasing worldwide demand for meat has led to anti-
biotic consumption in animals rising by 70 % over the
past decade [35]. As a result, two thirds of antimicrobial
consumption globally is linked to farm animals, often
with limited oversight by trained veterinary personnel
Fig. 1 Consumption of antibiotics in 2010 and evolution of consumption per capita between 2000 and 2010. Legend: Consumption of antibiotics
in 2010 expressed in standard units (ie, pill, capsule, or ampoule) per person, and percentage change in consumption per capita between 2000
and 2010. Reproduced with permission from CDDEP (Resistance Map: http://resistancemap.cddep.org/). Source: IMS MIDAS International Prescription
Data, January, 2000–December, 2010, IMS Health Incorporated. All Rights Reserved. The statements, findings, conclusions, views, and opinions
contained and expressed herein are not necessarily those of IMS Health Incorporated or any of its affiliated or subsidiary entities
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[36]. Mexico, Brazil, Australia, New Zealand and
Vietnam have adopted and implemented partial bans on
the use of antimicrobials for promoting growth in farm
animals. The European Union banned such practices in
2006 [37], but by 2012 some 8000 tons of antibiotics were
still being delivered to animals, with large variations be-
tween countries [38]. In the United States, recent policy
changes in the veterinary field include a ban on the use of
fluoroquinolones for poultry production and a ban on off-
label administration of cephalosporins to food animals
[39]. But for the other antibiotic classes used for growth
promotion, withdrawal is voluntary and no limits have
been imposed on their routine and often continuous in-
feed or in-water use for disease prevention or therapy. On
a voluntary basis, a growing number of food companies
are banning the use of meat produced using antibiotics to
promote growth, and the efficacy of these practices on
weight gain is marginal and dwindling [40].
From March to June 2014, WHO performed a global
Point Prevalence Survey of multidrug-resistant (MDR)
organisms in healthcare settings. Through an online survey,
it collected data from 420 laboratories in 67 countries on
selected bacterial pathogens isolated from inpatient clinical
blood and urine samples. Up to 10 % of the participating la-
boratories did not fulfill minimum criteria for quality con-
trolled detection of AMR and thus were excluded from the
analysis. This survey revealed wide regional variations for
extended-spectrum β-lactamase (ESBL)-producing Escheri-
chia coli and Klebsiella spp isolates (11.8–58.5 % and 35.1–
57.3 %, respectively) and methicillin-resistant Staphylococ-
cus aureus (MRSA) (27.7–44.4 %).
As an outcome of the 4th World HAI/Resistance
Forum held in 2013, the Global Point Prevalence Survey
(Global-PPS) was launched in 2014 to monitor rates of
antimicrobial prescription and resistance in hospitals
worldwide [41]. The Global-PPS is based on a standar-
dised protocol and validation process to ensure the col-
lection of comparable data among adults, children or
neonates across different types of wards. A simple web-
based interface allows data entry from a wide range of
geographical settings, and returns detailed analyses of
antibiotic use and prescription practices. It also provides
benchmarking tools at national, continental and global
levels, and identifies potential areas for improvement.
All tools are freely available to any hospital in the world
(www.global-pps.com). This survey invited hospitals
worldwide admitting adults, children and neonates, to
volunteer to participate. Data collected included age,
gender, weight, antimicrobial agents, doses, reasons and
indications for treatment, microbiological data, compli-
ance to guidelines, documentation of reasons and stop/
review date of prescription. Denominators included the
total number of inpatients. A web-based application was
used for data-entry, validation and reporting. Time frame
of data collection was from February until September
2015. As of June 2015, 223 hospitals from 44 countries in
Africa, Asia, Europe, North- and South-America and
Oceania, participated. The final results will be released in
November 2015 and are expected to include data from
700 hospitals in more than 70 countries.
Antibiotic use at national level
Data from the European Surveillance of Antimicrobial
Use and the European Antimicrobial Resistance Surveil-
lance System have shown that European Union countries
have been at least partially successful in controlling
AMR. The various rotating European presidencies have
allowed bottom-up initiatives to gain momentum within
member states and to translate into Council recommen-
dations. Strong leadership, with close links between
opinion leaders, policy makers and politicians in support
of AMR research has also provided evidence for success-
ful public health interventions.
In Australia, data from the national surveillance sys-
tem has revealed a rather high outpatient antibiotic use,
at some 25 DDD per 1000 inhabitants per day, as com-
pared to European countries (20 DDD per 1000 inhabi-
tants per day). Conversely, the quinolone use in
outpatients is among the lowest worldwide, at about 0.4
DDD per 1000 inhabitants per day [42].
A country-wide Point Prevalence Survey performed by
the US Centers for Disease Control and Prevention
(CDC) has estimated that around half of hospitalised pa-
tients receive antibiotics, and a quarter receive at least
two classes of antibiotics. Only four drugs and a handful
of conditions accounted for nearly half of the total anti-
microbial use [43].
Countries of the Arabian Peninsula have reported a
significant increase in antimicrobial resistance over the
past decade [44–46]. Unrestricted dispensing of anti-
microbial agents in both humans and animals are crit-
ical factors driving such resistance. In addition, the lack
of knowledge of some physicians about antibiotics and
their potential side effects continues to drive over-
prescription [32].
Antimicrobial resistance at national level
Data gaps are largest where health systems are weakest.
As a result, the burden of drug-resistant infections in
LMIC remains poorly described, but appears to be
greater than in high-income countries [47].
At the global level, the worst threat comes from the
emergence and rapid spread of MDR Gram-negative bac-
teria. It is a common concern in intensive-care units across
Europe [48], and in Latin America and most of the Arabian
Peninsula countries, in which Gram-negative bacteria have
become more frequent than Gram-positive bacteria in
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hospital-acquired bloodstream infections, with a significant
proportion of MDR strains [49, 50].
In particular, carbapenem-resistant Enterobacteriaceae
(CRE) are of major concern, as few treatment options
exist. In the Arabian Peninsula, the proportion of MDR
Gram-negative bacteria exceeds 50 % in some hospitals,
with carbapenem-resistant and ESBL-producing patho-
gens constantly rising [45]. Facing similar problems in
2010, the Greek island of Crete set up surveillance
through the PROCRUSTES programme, which had con-
siderable success in containing the incidence of MDR
Gram-negative bacteria in intensive-care units. In Croatia,
the national surveillance system in place since 1996 played
a key role in containing an outbreak of carbapenem-
resistant Acinetobacter baumannii in 2011. Unfortunately,
many hospitals worldwide still lack the required resources
for the adoption of effective infection prevention and con-
trol measures, such as isolation or cohorting capacities
[51]. They also lack methods to ensure the proper initi-
ation, justified continuation and prompt de-escalation of
antibiotics use, which collectively are referred to as anti-
microbial stewardship programmes.
The role of asymptomatic carriers of antibiotic resist-
ance genes among humans and animals is of concern. A
study on the prevalence, socio-demographic and hygiene
profile of patients at a tertiary-care public hospital in
Pakistan concluded that poor access to sanitation was an
important predictor of carbapenemase carriage [52]. It
revealed that 95 % of patients carried some form of
AMR, and 20 % of these carried a New Delhi metallo-β-
lactamase (NDM) variant of CRE. Fortunately, many of
the bacteria carrying these forms of resistance were not
clinically relevant, but their ubiquity is worrisome as a
potential source of horizontal gene transfer to patho-
gens. The study did not find carbapenemase carriage be-
ing driven by previous antibiotic consumption, but
among NDM carriers, previous exposure of carriers to
heavy metals was a strong explanatory factor; mobile
genetic elements carrying NDM often also carry genes
conferring resistance to heavy metals [52].
Finally, CRE are also spreading among humans in the
community with worrying implications for public health.
The prevalence of carbapenemases in the healthy popula-
tion in India has been estimated at 7.4 %, and its incidence
in intensive-care unit patients at 27.4 % [53]. Other forms
of resistance among Gram-negative bacteria not related to
β-lactams or carbapenems are also becoming critical in
India and in other countries, with resistance rates as high
as 73 % against fluoroquinolones in E. coli [54].
Spread of antimicrobial resistance between humans,
animals and the environment
Growing human and animal populations, international
travel and trade, as well as contact with wildlife all
contribute to spreading AMR and making it a global
health concern. Beyond international collaboration, a
One Health perspective is urgently needed as AMR in-
volves a dynamic and complex web of interactions; there
are many paths by which drug residues and resistant
bacteria can disseminate between humans, animals and
the environment (Fig. 2).
The highest concentrations of antibiotics and resistant
bacteria have been recorded in effluents released from
hospitals and drug manufacturing sites in developing
countries [55–57]. In certain cases, drinking water can
also play a role in dissemination, as demonstrated by
CRE detected in 9 out of 19 samples of the New Delhi
chlorinated water supply [58].
The food chain also has a role in spreading resistance.
Resistance in the food-borne bacteria Salmonella and
Campylobacter is clearly linked to antibiotic use in food
animals, and food-borne diseases caused by such resist-
ant bacteria are well documented in people [59, 60]. In a
One Health perspective, food-borne E. coli is even more
worrying as it is frequently found in retail meat and is
often associated to critical ESBLs [61]. In the United
States for instance, a 2013 survey revealed a 65 % preva-
lence of E. coli in retail chicken products. Some of these
were extra-intestinal E. coli (ExPEC) that closely resem-
bled E. coli isolates found in humans regarding phylo-
genetic group, serotype distribution and virulence
factors. In chickens, ExPEC isolates had on average three
more virulence-related genes than non-ExPEC isolates,
but there were no significant differences in phenotypic
resistance [62].
Whole genome sequencing has also demonstrated that
strains of E. coli isolated from retail turkey, chicken, or
pork products correspond closely with the etiologic
agents of human urinary tract infections occurring in
the same locale where the foods were purchased, sug-
gesting food-borne transmission of meat-source E. coli
to humans and subsequent disease. The transmission of
pathogenic strains from humans to animals has also
been documented, for example in the case of MRSA
type CC398 [63].
In addition, plasmids carrying ESBL genes have been
identified in Enterobacteriaceae of both human and ani-
mal origins. For instance, some non-ST131 E. coli from
cattle were shown to harbor plasmids carrying the
human-associated CTX-M-15 ESBL genes. And IncI1/
ST3 plasmids found in the microbiota of several animal
species have a role in the spread of CTX-M-1-types of
ESBL in E. coli [64].
Both Gram-positive and Gram-negative pathogenic bac-
teria of human origin have been reported in animals. The
same holds true for a large variety of clinically relevant re-
sistance genes, including VIM, NDM and OXA-48 like
carbapenemases, which have already been detected in
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pigs, dogs and several wildlife species [65]. Insects may
also play a role in these genetic transfers [66], but the
exact transfer rates and transmission routes are still un-
known. Hence, the relative contributions of the environ-
ment, livestock and humans to AMR are still debated
among experts [67].
The way forward for efficient surveillance
Obtaining a global picture for AMR is difficult due to a
lack of data and standardised surveillance methodolo-
gies. Recent WHO reports on AMR have highlighted
major gaps in this area and call for closer collaboration
between surveillance networks at national and inter-
national levels [18].
Countries that have adopted strategies against AMR
have all included the establishment of national surveil-
lance systems in their policies. Yet, despite WHO’s call
to apply surveillance to all sectors using a One-Health
approach, few countries now combine human, animal,
food and environmental data in their reporting. In this
regard, Denmark, Sweden and Norway have led the way,
demonstrating how joint responsibility-taking by health,
agriculture and environment authorities can result in ro-
bust surveillance systems. Recently, several other countries
have followed suit. For instance Argentina, South Africa
and the Gulf Cooperation Council have announced their
intention to embrace a One Health approach against AMR.
The Australian Ministries of Health and of Agriculture have
Fig. 2 Potential routes of transmission of antibiotic-resistant bacteria. Legend: Humans in the community or in hospitals, pets, livestock and fish
farms rely on similar classes of antibiotics to fight infectious diseases. Both pathogenic and non-pathogenic bacteria evolve or exchange the
ability to survive when exposed to these antibiotics. They spread into the environment through different routes, such as water sanitation systems
(1), as wastewater treatment facilities do not entirely remove antibiotic resistant bacteria before releasing water into the environment. Another
common route is through the application of manure to fields with cultivated crops (2), where antibiotic resistant bacteria can readily develop on
the plants (3). The uptake of these resistant bacteria can then happen through the food chain, when humans later consume these plants (4) or
the contaminated flesh of animals and fish harbouring resistant bacteria (5). As bacteria can easily reach water reserves, water distribution infrastructure
is also a potential route for the spread of these germs (6). Even wildlife, insects and other bugs are potential carriers of antimicrobial resistance (7).
Tourism, migrations and food imports (8) are nevertheless reported as the fastest way of spreading resistant strains of bacteria across borders. At the
healthcare facilities level, resistant bacteria can spread by contact between patients or with healthcare staff, or through contaminated surfaces and
medical devices. Reproduced with permission from bioMérieux (modified)
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issued a common strategy and have expanded surveillance
through a One Health approach (with a list of monitored
species now longer than the list recommended by WHO).
Additionally, the US national action plan against AMR also
calls for enhanced efforts, including better surveillance, in
both human and animal sectors.
At country scale, there remains scope to improve the
convergence of existing surveillance systems. In the
United States, for instance, several monitoring networks
(such as the National Healthcare Safety Network, the
National Antimicrobial Resistance Monitoring System,
and the Emerging Infections Program) focus on different
settings or different pathogens; aggregating their data
provides useful insights for enhancing the management
of infectious diseases as a whole.
Surveillance gaps include the fact that many surveil-
lance systems focus on hospitalised patients, leaving
community settings under-represented. For use data, the
opposite is true; for many countries, there is more data
on use in the community then in hospitals. But in many
cases, data on antibiotic consumption is not collected
with corresponding information on clinical indications;
as a result, characterising antibiotic misuse often re-
mains challenging. The burden of disease associated
with AMR is also poorly documented; surveillance sys-
tems should ideally track the clinical outcomes related
to antibiotic resistance.
Sanitation, hygiene and infection prevention
measures
The first among infection prevention and control (IPC)
measures to contain AMR spread is hand hygiene. Im-
proving hand hygiene is an essential approach to combat
AMR. The WHO’s global “Clean Care is Safer Care”
campaign, launched in 2005, has been an opportunity
for many countries to learn how to adapt a global campaign
to national needs, in order to achieve local buy-in [68, 69].
It relies on a multi-modal strategy for implementation, with
many practical tools, illustrations and straightforward,
catchy phrases. The campaign empowers countries to par-
ticipate through pledges by their health ministries, and has
a self-assessment framework that could serve as a blueprint
for a similar tool that would assess – and enhance the visi-
bility of – efforts toward antimicrobial stewardship in hos-
pitals. After 10 years of operation and deployment through
179 countries, the “Clean Care is Safer Care” campaign has
achieved a 50 % reduction in hospital-acquired infections
through improved hand hygiene, and has contributed to
saving an estimated 7 or 8 million lives per year [70].
Australia joined WHO Clean Care is Safer Care in
2006. More than 850 health facilities participate in the
country’s National Hand Hygiene Initiative, which has
played a major role in the decline of MRSA cases in hos-
pitals [71]. This is probably the world’s largest hand
hygiene education and compliance monitoring
programme, and includes a comprehensive set of tools –
including apps for mobile devices – to ensure data col-
lection and compliance.
In India, vaccination and hygiene-related policies have
made impressive progress, with full immunization cover-
age of children now approaching the 90 % mark, and the
country pledged to become “open defecation free” by
2019, with plans to build 120,000 toilets in rural India
by October 2019, at a projected cost of US$31 billion.
The Gulf Corporation Countries have also adopted
strategies to enhance IPC as early as 2009. The countries
of the region adopted both a robust infection control
manual and a surveillance manual for healthcare-
associated infections (HAIs), to be updated in 2015.
Infection control of critical Gram-negative bacteria
With the rise of pan-resistant Gram-negative bacteria,
IPC measures are all the more vital for controlling out-
breaks. There is no single strategy to fit all situations,
but a few important lessons have been learned in this
field.
In Israel, an outbreak of multidrug-resistant A. bau-
mannii was kept in check by accurately and rapidly
identifying the origin of the outbreak, which in this case
was multiple (there were several concurrent outbreaks)
[72]. As transmission routes are rarely uniform, the
mapping of the “transmission opportunities” proved to
be a good way of pinpointing high-risk patient groups.
Patient screening is a powerful tool for identifying
transmission routes and targeting interventions. Active
surveillance has often demonstrated a significant impact
on reducing CP-CRE incidences, but remains a subject
of ongoing debate [73]. While planning for screening
procedures, it is also important to consider subsequent
costs to reduce transmission, such as isolation or cohort-
ing of colonised patients.
Deciding which parts of the body need to be screened
is not always straightforward. Screening for Acinetobac-
ter species may require skin, pharynx, tracheal, or peri-
anal samples. Detection of Pseudomonas species may
prove most complicated, as they do not selectively col-
onise any particular part of the body [73].
Basic IPC measures – including hand hygiene, proper
use of personal protective equipment (PPE), proper
cleaning and disinfection of the environment and med-
ical equipment, and patient and visitor crowd control –
are always required, but may be difficult to implement in
many healthcare settings around the world. Use of anti-
septic baths or wipes have been reported to have a sig-
nificant impact on reducing Acinetobacter incidence,
and environmental hygiene is an important adjunct
measure that requires particular attention with pan-
resistant Gram-negative bacteria [74].
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France has adopted a set of guidelines for identifying
CRE in clinical specimens and fecal screening. Since 2013,
a set of guidelines to deal with critical MDR organisms as
soon as they are detected is also being enforced (Table 2).
These guidelines led to contain the spread of MRSA, VRE
and carbapenemase-producing enterobacteriacae in a
large set of French public hospitals [75].
Use of antimicrobial medicines in human and
animal health
Prudent use of existing antibiotics must be a priority, be-
cause their consumption is one of the main drivers of
AMR [76]. Bans or restriction policies have proved ef-
fective in curbing resistance in some settings [77, 78],
and have achieved impressive results in the veterinary
sector [79]. Persuasive approaches may also be highly
successful, if well-designed and implemented [80]. An-
other advantage of implementing stewardship programs
is the resulting reduction in the various side effects of
antibiotics [81]. One of their most common adverse
events is the difficult-to-treat – and sometimes fatal –
diarrhoea caused by Clostridium difficile infection, a
condition likely to remain of high concern [82].
Despite strong evidence about the cost-effectiveness of
stewardship interventions, the vast majority of AMR-
related resources are currently allocated to the develop-
ment of new antibiotics. This may not be the best
strategy, because if we develop new agents and do small
interventions in all the other areas, history is likely to re-
peat itself; any new drug will lose its effectiveness as
soon as resistance develops in bacterial strains [83]. The
Center for Disease Dynamics, Economics & Policy
(CDDEP) recently estimated that investing US$ 50 million
in an antibiotic stewardship programme can “buy” one full
year for the billion-dollar research and development pro-
grammes in the United States that are trying to bring new
antibiotics to the market [84].
In hospitals, prophylactic prescriptions of antibiotics
should be the first target of stewardship interventions.
Although this practice is necessary for certain periopera-
tive and surgical procedures, treatment should not ex-
tend beyond 24 h (most frequently, a single dose is
sufficient). Yet, longer regimens continue to be used in
many healthcare settings around the world [85]. Some
facilities have their own antibiotic prescription guidelines
against which to verify compliance, but most hospitals
still lack such a tool [86].
An analysis of a subset of antibiotic use data collected
for the Point Prevalence Survey performed by the CDC
in 2013 suggests that there are two further low hanging
fruits for inpatient stewardship interventions. First, the
treatment of urinary tract infections because nearly 40 %
of such antimicrobial prescriptions were inappropriate,
and second, vancomycin use, because in many cases
treatment was continued for more than three days
Table 2 Summary of the French guidelines to deal with critical MDR organisms
Main steps Main causes of failure observed
Isolating the patient, at best cohorting and dedicated staff – Delayed measures (e.g., patients admitted over the week-end or
medical staff not reacting quickly)
– Lack of dedicated healthcare workers to implement
isolation or cohorting
– Missing readmission /admission screening of a patient known to carry a
MDR organism
– Missing information on a previous stay of the patient in
another hospital, particularly in a foreign country
Alerting hospital management – Mistakes in the hospital management system
– Loose relationship between the infection control team and
hospital management
Stopping transfers of patients to other hospitals – Continuation of patient transfers to other hospitals
Screening any people who may have been in
contact with the patient
– Uncompleted list of contacts
– Not sampling identified contact patients
– Missing admission of a patient transferred from a ward or
hospital where outbreak is ongoing
– Inadequate lab facilities
Reinforcing hand hygiene – Poor hand hygiene at baseline
– Insufficient input of infection control team
Identifying antibiotics that could be used in case
of critically-resistant infections
– Delayed identification by the laboratory
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without evidence of an infection caused by a resistant
Gram-positive organism [87].
Antimicrobial stewardship in animal health
Denmark implemented stewardship programs in the vet-
erinary sector as early as 1998. As a result, the amount of
antimicrobials consumed per kilogram of pig meat pro-
duced was reduced by 50 % from 1994 to 2013 [88, 89].
Other successful examples of antimicrobial conservation
in animal health are depicted in Table 3.
In 2011, a sharp increase of resistance to cephalosporins
was detected in bacteria colonising indigenous broilers.
This observation was unexpected, because this class of an-
tibiotics had not been used on Danish broilers for 10 years.
The explanation came from the UK, where the ancestors
of the Danish broilers had been raised and had received
cephalosporin treatments in their youth, selecting for
ESBL-producing bacteria which were then transmitted to
their offspring [93]. This is another demonstration of how
the usage of antimicrobials in one country can affect re-
sistance levels in another. In fact, the very intensive ex-
change of livestock within and between countries has
important implications for control strategies.
Stopping the use of antibiotics as growth promoters in
food animals is a long awaited measure that has been
implemented in only a limited number of countries to
date. A sparing use of antimicrobials for prophylaxis and
therapy is also crucially needed [94]. In any case, food
animals should not be treated with “critically important”
or “last line” antibiotics for humans (namely, glycopep-
tides, fluoroquinolones, 3rd generation cephalosporins,
carbapenems). Regulations on this important issue are
scarce or non-existing.
New medicines, diagnostic tools, vaccines and
other interventions
Therapeutic challenges posed by pan-resistant Gram-
negative bacteria
CRE can be considered as one of the plagues of the early
21st century, as they are associated with drastically
increased mortality, length of stay, and cost of treatment
[95]. A study on neutropenic and non-neutropenic pa-
tients documented a 63 % mortality rate (at 28 days)
among patients with bacteremia caused by carbapenem-
resistant strains vs 38 % among those infected by
carbapenem-sensitive strains [96].
Worryingly, the mean duration of CRE carriage follow-
ing hospital discharge has been estimated to 387 days
(95 % CI; 312–463) [97]. And co-carriage of several
other carbapenemases seems to be common, further in-
creasing the risk of treatment failure [98].
New drugs against MDR Gram-negative bacteria
should become available in the near future, but it is un-
likely that any of them will prove effective against all
existing carbapenemases [99]. For the time being, critical
MDR infections often require the use of old drugs and
combination therapies, which frequently induce larger
side effects and morbidity. Unfortunately, very limited
evidence exists about the efficacy of these treatments,
for instance the colistin-imipenem-tigecycline combin-
ation to treat carbapenem-resistant bacteria. Some studies
with limited datasets have demonstrated the superiority of
combination therapies [100, 101], whereas others did not
show any significant difference [102, 103]. While studies
based on larger samples are urgently needed to determine
the best treatment options, resistance to these last-resort
classes of antibiotics is also rising in several Gram-
negative bacteria [104, 105], probably due to increased
consumption: for example, between 2000 and 2010, the
global use of carbapenems and polymyxins increased 45
and 13 %, respectively [2].
Alternatives to antibiotics
Streamlining and facilitating the development of new an-
timicrobials is a necessary but costly option, [106] and
bacterial resistance to these compounds has always
emerged quickly. For many classes of antibiotics devel-
oped so far, resistance emerged on average five years
after commercial release of the compounds (Fig. 3);
Table 3 Successful examples of antimicrobial stewardship in animal health
Country Main measures implemented Observed effects
Australia Fluoroquinolones (FQ) not approved for livestock
use
Levels of FQ resistance among Escherichia coli in humans are among the lowest registered.
FQ resistance in Escherichia coli is absent in food animals and foods. There are no FQ
resistant strains of Campylobacter spp. or Salmonella spp. seen in food animals
or domestic foods [90]. FQ resistance is absent or only at very low levels in
domestically acquired Campylobacter or Salmonella infections in people.
Canada Voluntary withdrawal of ceftiofur in ovo use. Thirty months later, resistance levels cut by half in Salmonella enterica from
chicken meat and humans and in retail chicken Escherichia coli [91].
Denmark Ceasing antibiotic growth promotion in
weaning pigs
Ten years after, the average daily weight put on by each animal was 20 % higher
than before the ban, demonstrating that weight gains in livestock are achievable
by other means than antibiotics [88].
Netherlands Usage of fluoroquinolones and third and fourth
generation cephalosporins reduced to a minimum
Antimicrobial consumption in animals fell 56 % from 2007 to 2012 [92].
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some resistance mechanisms were already present even
before the commercialisation of the agent.
Most national strategies against AMR recognise the
urgent need for new antibiotics, but also for alternative
solutions to circumvent the resistance problem. These
may include probiotics and prebiotics, drugs targeting
bacterial communication or virulence, therapies based
on bacteriophages or phage enzymes, or those harnes-
sing the power of the immune system, such as antibodies
or vaccines. Vaccination may not work against all bacter-
ial strains, but it shows great promises against some,
such as uropathogenic E. coli (UPEC) strains responsible
for the majority of urinary tract infections.
New tools for better surveillance
Currently, culture is the key component in the detec-
tion and preliminary identification of MDR organisms.
A variety of rapid diagnostic tests and selective media
has been developed and used with great success in de-
fining intra- and inter-individual colonisation and in-
fection rates. The methods are easily available, well
accepted, and affordable, but take time and effort. New
diagnostic tools based on protein identification (e.g., mass
spectrometry, biochemical or immunological techniques)
are increasingly available at lower costs, as are tests char-
acterising other biomolecules, including for instance lipids
and sugars. These can provide further epidemiological in-
sights – compared to simple phenotypic tests – and many
of them are easy to use in routine laboratory work [107].
Gene identification, which relies on the detection of
known resistance genes, is also becoming more access-
ible, but some of the commercially available tests are un-
able to discern between gene variants (for instance
between oxacillinases 48, 163, and 405). False positives
can also be an issue, as detected resistance genes may be
present in non-pathogenic bacteria, or corresponding
minimum inhibitory concentrations can in fact be very
low. In addition, genes may be present but expressed
poorly or not at all.
Progress has been made with genome sequencing – now
available at lower costs. It delivers results within 18–24 h
and, through the identification of clonal relationships, could
be a powerful tool to reveal the source of an outbreak and
its dissemination routes. For instance, the genetic mapping
of integrons during a small outbreak of KPC-2 in
Israel revealed its route of transmission and complex
polyclonal evolution, involving several intermediate
hosts (E. cloacae - > E. coli - > K. pneumoniae) [108].
Fig. 3 Commercialisation and first detection of resistant bacteria for some classes of antibiotics. Legend: Classes of antibiotics which disrupt the
synthesis of the bacterial cell envelope are depicted in orange, those inhibiting the bacterial protein synthesis are depicted in blue, and those
interfering with the metabolism of nucleic acids in bacteria are depicted in green. Empty boxes indicate molecules for which resistance has been
documented prior to commercialisation. * Resistance to penicillin was observed by Fleming himself even prior to its widespread availability and
commercialisation. ** Aminogylcosides: The first mutants resistant to streptomycin were reported as early as 1946, whereas its commercial
introduction dates back to 1948 [113]. *** 5th generation cephalosporins: ceftaroline resistance was documented prior to its commercial
introduction in 2010 [114]
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Finally, in some cases, genome sequencing has also
proved to be more robust than phenotypic antimicrobial
sensibility testing [109]. Still, genomic epidemiology needs
to be further calibrated taking into account genome-wide
mutational frequencies during dissemination or growth
under unfavorable conditions. In addition, the technology
should be simplified and data interpretation and reporting
should be automated.
Conclusion
Lectures and discussions during the fifth World
Healthcare-Associated Infections Forum highlighted some
measures of progress along the most urgent priorities for
action cited by participants of the Forum’s earlier editions
[110, 111]. While the best strategies to curb AMR are be-
coming obvious, isolated country based efforts will not be
sufficient and further research is direly needed in several
fields. The links between antibiotic use and resistance genes
that circulate in livestock, humans and the environment re-
main poorly understood; for instance, available data do not
allow accurate quantification of the contribution of anti-
microbial consumption in one sector to resistance in an-
other. Our understanding of the ecological roles of
antibiotics in nature is incomplete, in particular regarding
the effects of sub-inhibitory levels in the environment; the
levels of antibiotic contamination at which resistant bacteria
are selected for and horizontal gene transfer is facilitated
should be determined [112]. Further investigation of “cross
resistance” and “co-selection” mechanisms is also war-
ranted. Last but not least, more investments are required
for enabling behaviour change.
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